The Gene-virus Therapy Of A New Kind Of Dual-targeting Replicated Adenovirus For Cancer

In order to have safty clinical practice of oncolytic adenovirus, a novel dual-targeting tumor specific proliferating virus AdCN103 has been constructed by replacing the normal wild type adenovirus E1A promoter with the promoter of human telomerase reverse (hTERT) and mutant E1A lacking CR2 region. AdCN103-IL24 which the IL-24 gene is inserted to the AdCN103 has been generated in order to kill the tumor cells completely.Killing effect of AdCN103 on several different tumor cell lines and normal cell lines were detected by crystal violet dye method and MTT assay and the virus replicating ability was assessed by virus progeny assay. It turns out that the AdCN103 can only strictly replicated in tumor cell lines and had an overt cytopathic effect. Meanwhile, there was a dramatic reduction of cytotoxicity in normal cells infected with AdCN103 compared with its corresponding control vectors, which proves that such protocol may have important applications for cancer gene therapies in the future. AdCN103-IL24 can kill the tumor cells specially and effectively. The datas from in virto and in vivo experiments make the basis to construct the dual gene-targeting oncolytic adenovirus.